desk
Share
News Topical, Digital Desk : Mumbai-based pharmaceutical company Lupin has provided information about its New Jersey manufacturing facility. The company stated in an exchange filing that the United States FDA has completed a pre-approval inspection at the facility in Somerset, New Jersey. The inspection lasted from September 29 to October 10, 2025, after which one objection was issued. The company stated that it will resolve the objection and respond to the FDA within the stipulated timeframe.
The company also added that it is committed to ensuring compliance with CGMP standards in all its facilities. Earlier this week, Lupin announced plans to establish a new state-of-the-art pharmaceutical manufacturing facility in the United States. This facility will invest $250 million over the next five years. The facility will be located in Coral Springs, Florida, and will boost the production of critical respiratory drugs in the United States.
Share performance : On Friday, the stock closed at ₹1,959 per share, up 0.09 percent, or ₹1.70. Over the past three months, the company's stock has gained 3.41 percent.
Read More: Market this Week: Up to 41% return in a week, these stocks made strong profits
--Advertisement--
